IN8bio (NASDAQ:INAB) Earns “Buy” Rating from HC Wainwright

IN8bio (NASDAQ:INAB)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $8.00 price target on the stock.

IN8bio Trading Down 4.5 %

NASDAQ INAB opened at $0.30 on Tuesday. The company has a market cap of $21.47 million, a price-to-earnings ratio of -0.39 and a beta of -0.07. IN8bio has a twelve month low of $0.22 and a twelve month high of $2.48. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.05. The business’s fifty day moving average is $0.30 and its 200 day moving average is $0.63.

IN8bio (NASDAQ:INAB) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). As a group, sell-side analysts expect that IN8bio will post -0.56 EPS for the current fiscal year.

Hedge Funds Weigh In On IN8bio

A hedge fund recently raised its stake in IN8bio stock. Sigma Planning Corp boosted its stake in shares of IN8bio, Inc. (NASDAQ:INAB) by 42.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 851,280 shares of the company’s stock after buying an additional 251,600 shares during the quarter. Sigma Planning Corp owned approximately 1.82% of IN8bio worth $230,000 as of its most recent SEC filing. 92.05% of the stock is currently owned by institutional investors and hedge funds.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.